The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial
Abstract
AIM: Patients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic dilatation rate in Marfan patients. METHODS AND RESULTS: In this multicentre, open-label, randomized controlled trial with blinded assessments, we compared losartan treatment with no additional treatment in operated and unoperated adults with Marfan syndrome. The primary endpoint was aortic dilatation rate at any predefined aortic level after 3 years of follow-up, as determined by magnetic resonance imaging. A total of 233 participants (47% female) underwent randomization to either losartan (n = 116) or no additional treatment (n = 117). Aortic root dilatation rate after 3.1 ± 0.4 years of follow-up was significantly lower in the losartan group than in controls (0.77 ± 1.36 vs. 1.35 ± 1.55 mm, P = 0.014). Aortic dilatation rate in the trajectory beyond the aortic root was not significantly reduced by losartan. In patients with prior aortic root replacement, aortic arch dilatation rate was significantly lower in the losartan group when compared with the control group (0.50 ± 1.26 vs. 1.01 ± 1.31 mm, P = 0.033). No significant differences in separate clinical endpoints or the composite endpoint (aortic dissection, elective aortic surgery, cardiovascular death) between the groups could be demonstrated. CONCLUSION: In adult Marfan patients, losartan treatment reduces aortic root dilatation rate. After aortic root replacement, losartan treatment reduces dilatation rate of the aortic arch.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010)
Endorsed by the Association for European Paediatric Cardiology (AEPC), Authors/Task Force Members, Baumgartner, H., Bonhoeffer, P., De Groot, N. M. S., de Haan, F., Deanfield, J. E., Galie, N., Gatzoulis, M. A., Gohlke-Baerwolf, C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq249 · Cited by 2,331
Self-citationWRITING GROUP MEMBERS, Hiratzka, L. F., Bakris, G. L., Beckman, J. A., Bersin, R. M., Carr, V. F., Casey, D. E., Eagle, K. A., Hermann, L. K., Isselbacher, E. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181d4739e · Cited by 2,289
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Revised diagnostic criteria for the Marfan syndrome
De Paepe, A., Devereux, R. B., Dietz, H. C., Hennekam, R. C. M., & Pyeritz, R. E. (1996) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19960424)62:4<417::aid-ajmg15>3.0.co;2-r · Cited by 1,572
Shores, J., Berger, K. R., Murphy, E. A., & Pyeritz, R. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301902 · Cited by 1,071
Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome
Brooke, B. S., Habashi, J. P., Judge, D. P., Patel, N., Loeys, B., & Dietz, H. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706585 · Cited by 843
Extracellular control of TGFβ signalling in vascular development and disease
ten Dijke, P., & Arthur, H. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2262 · Cited by 778
Forest plots: trying to see the wood and the trees
Lewis, S., & Clarke, M. (2001) · BMJ · doi:10.1136/bmj.322.7300.1479 · Cited by 763
Life expectancy in the Marfan syndrome
Silverman, D. I., Burton, K. J., Gray, J., Bosner, M. S., Kouchoukos, N. T., Roman, M. J., Boxer, M., Devereux, R. B., & Tsipouras, P. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)80066-1 · Cited by 565
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
Erbel (2014) · doi:10.1093/eurheartj/ehu281 · Cited by 4,451
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Metadata
- Authors
- Groenink, M., den Hartog, A. W., Franken, R., Radonic, T., de Waard, V., Timmermans, J., Scholte, A. J., van den Berg, M. P., Spijkerboer, A. M., Marquering, H. A., Zwinderman, A. H., & Mulder, B. J. M.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-02
- Volume
- 34
- Issue
- 45
- Pages
- 3491-3500
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2134642866
- Cited by
- 396
- References
- 33
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. https://app.cochat.ai/papers/10.1093/eurheartj/eht334
- The paper
- Groenink, M., den Hartog, A. W., Franken, R., Radonic, T., de Waard, V., Timmermans, J., Scholte, A. J., van den Berg, M. P., Spijkerboer, A. M., Marquering, H. A., Zwinderman, A. H., & Mulder, B. J. M. (2013). Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. European Heart Journal. https://doi.org/10.1093/eurheartj/eht334
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
